KLRK1 and Miyoshi myopathy: A NK-specific BCMA-targeted CAR constructed from 4 transgenes and intracellular signaling modalities derived from NKG2D, 2B4, and CD3ζ has shown translational results with potent antitumor activity against MM in various mice models (40).